POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced the appointment of David E. Moller, MD, as Chief Scientific Officer (CSO).

https://www.poxelpharma.com/en_us/investors/news-events/press-releases/detail/142/poxel-appoints-industry-leader-dr-david-e-moller-as-chief